Ernexa Therapeutics Advances ERNA-101 Development, Plans IND Submission in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 27 2026
0mins
Ernexa Therapeutics announced progress in the development of ERNA-101, the company's therapeutic candidate, achieving multiple milestones that position the program for a planned investigational new drug submission in the third quarter of 2026 and the anticipated initiation of its first-in-human clinical study. The company has successfully completed process development activities for the ERNA-101 manufacturing process and has now transitioned into Good Manufacturing Practice, or GMP, manufacturing in preparation for clinical development. In parallel, technology transfer activities for ERNA-101 are actively underway, representing another major operational milestone supporting the planned IND submission timeline. IND submission for ERNA-101 targeted for Q3.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERNA
About ERNA
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ernexa's Innovative Advances in Ovarian Cancer Treatment
- Challenges in Ovarian Cancer Treatment: Dr. Elena Ratner from Ernexa Therapeutics highlights that ovarian cancer remains one of the most challenging malignancies to treat, with patients facing significant hurdles during diagnosis and treatment, underscoring the urgent need for more effective therapies to improve survival rates.
- Potential of ERNA-101: Newly released preclinical data indicates that ERNA-101, when combined with PD-1 blockade, achieves complete tumor elimination and 100% long-term survival in ovarian cancer models, showcasing its substantial potential in therapeutic applications.
- Innovation in Cell Therapy: Ernexa's engineered allogeneic induced mesenchymal stem cell (iMSC) platform offers a scalable, off-the-shelf cell therapy solution designed to enhance accessibility and overcome manufacturing challenges associated with traditional autologous therapies, presenting significant market opportunities.
- Future Treatment Landscape: As the ovarian cancer treatment landscape evolves, Ernexa's biological approach provides new strategies to address immunologically
See More
Ernexa Therapeutics Reports Significant Loss Narrowing in Q1
- Significant Loss Narrowing: Ernexa Therapeutics reported a Q1 net loss of $5.51 million, an improvement from $8.20 million last year, indicating positive financial progress that may boost investor confidence.
- Therapy Success Rate: The company's latest ERNA-101 therapy achieved 100% long-term survival and completely cleared tumors in mouse models, demonstrating its potential in ovarian cancer treatment and laying the groundwork for future clinical trials.
- Stock Surge: Following the positive earnings report and optimistic therapy outlook, Ernexa's shares soared over 90% on Tuesday, reflecting strong market interest in its biotech stock and potentially attracting more investors.
- Clear Future Plans: CEO Sanjeev Luther stated that the company aims to submit an Investigational New Drug application by Q3 2026 and plans to initiate a Phase 1 human trial later this year, indicating ongoing commitment to R&D and strategic direction.
See More
Ernexa's Innovative Advances in Ovarian Cancer Treatment
- Unmet Need in Ovarian Cancer: Dr. Robert Pierce, Chief Scientific Officer of Ernexa, emphasizes the significant unmet need in treating ovarian cancer, one of the most challenging malignancies, highlighting the urgent demand for more effective and durable treatment options to enhance patient quality of life and outcomes.
- Potential of ERNA-101: Recent preclinical data shows that ERNA-101, when combined with PD-1 blockade, achieved a remarkable 100% survival rate and complete tumor elimination in ovarian cancer models, indicating its potential to significantly improve patient prognosis and treatment efficacy.
- Virtual Investor Event: Ernexa will host a Virtual Investor Closing Bell event on May 13, 2026, where executives will present the latest developments of ERNA-101 and discuss its application potential in ovarian cancer treatment, further boosting investor confidence in the company's future growth.
- Innovation in Cell Therapy: Ernexa focuses on developing innovative cell therapies using induced pluripotent stem cell technology to provide scalable treatment solutions, with ERNA-101 designed to activate and regulate the immune response to recognize and attack cancer cells, showcasing its strategic significance in cancer treatment advancements.
See More
Ernexa Therapeutics Exceeds Expectations with Promising Therapy Results
- Therapy Advancement: Ernexa Therapeutics announced that its ERNA-101 cell therapy achieved 100% long-term survival and complete tumor clearance in mouse models, exceeding company expectations and demonstrating significant potential in advanced ovarian cancer treatment.
- Clinical Trial Plans: The company plans to advance ERNA-101 to its first human trial, which is expected to significantly shift treatment outcomes in ovarian cancer and may extend to other immunologically suppressed tumors, enhancing treatment effectiveness.
- Market Reaction: Following the announcement, Ernexa's stock surged 60% on Wednesday, reflecting investor optimism about its preclinical results, with retail sentiment shifting from neutral to extremely bullish, with some expecting a 200% rally.
- Peer Updates: The release of Ernexa's trial results coincided with Zentalis Pharmaceuticals announcing progress in its treatment for platinum-resistant ovarian cancer, further increasing market interest in ovarian cancer therapies.
See More
Ernexa Therapeutics Reports Breakthrough in Cancer Treatment
- Tumor Clearance Rate: Ernexa's ERNA-101 combined with PD-1 blockade achieves a 100% tumor clearance rate in ovarian cancer models, indicating potential curative activity that could transform treatment paradigms for ovarian cancer.
- Microenvironment Remodeling: ERNA-101 remodels the tumor microenvironment from immunosuppressive to immune-activated, enhancing anti-tumor immune responses and suggesting applicability in other solid tumors.
- Enhanced Cell Activity: The therapy significantly boosts the activity and survival of key cancer-fighting T cells, facilitating greater infiltration of CD4⁺ and CD8⁺ T cells into tumors, potentially offering more effective treatment options for patients.
- Clinical Trial Prospects: Ernexa plans to incorporate these positive preclinical findings into its development strategy, advancing ERNA-101 towards a first-in-human clinical trial for advanced ovarian cancer, signaling the company's strategic positioning in tumor immunotherapy.
See More
Ernexa Therapeutics to Implement 1-for-25 Reverse Stock Split
- Reverse Stock Split Plan: Ernexa Therapeutics announced a 1-for-25 reverse stock split effective May 4, 2026, aiming to consolidate every 25 shares into 1 to comply with Nasdaq's minimum bid price requirement of $1, thereby enhancing the stock's market performance.
- Reduction in Shares: This split will reduce the company's outstanding shares from approximately 29.15 million to about 1.17 million, significantly lowering the share count, which may impact investor liquidity and attractiveness towards the stock.
- Market Reaction: Following the reverse split announcement, ERNA shares fell 25% in premarket trading, reflecting market concerns regarding the company's current financial condition and future outlook, which could undermine investor confidence.
- Compliance Pressure: This move not only addresses Nasdaq compliance but also indicates the company's urgency in improving its market image and shareholder value, potentially affecting its future financing and strategic development plans.
See More
Ernexa's Innovative Advances in Ovarian Cancer Treatment
- Challenges in Ovarian Cancer Treatment: Dr. Elena Ratner from Ernexa Therapeutics highlights that ovarian cancer remains one of the most challenging malignancies to treat, with patients facing significant hurdles during diagnosis and treatment, underscoring the urgent need for more effective therapies to improve survival rates.
- Potential of ERNA-101: Newly released preclinical data indicates that ERNA-101, when combined with PD-1 blockade, achieves complete tumor elimination and 100% long-term survival in ovarian cancer models, showcasing its substantial potential in therapeutic applications.
- Innovation in Cell Therapy: Ernexa's engineered allogeneic induced mesenchymal stem cell (iMSC) platform offers a scalable, off-the-shelf cell therapy solution designed to enhance accessibility and overcome manufacturing challenges associated with traditional autologous therapies, presenting significant market opportunities.
- Future Treatment Landscape: As the ovarian cancer treatment landscape evolves, Ernexa's biological approach provides new strategies to address immunologically
See More
Ernexa Therapeutics Reports Significant Loss Narrowing in Q1
- Significant Loss Narrowing: Ernexa Therapeutics reported a Q1 net loss of $5.51 million, an improvement from $8.20 million last year, indicating positive financial progress that may boost investor confidence.
- Therapy Success Rate: The company's latest ERNA-101 therapy achieved 100% long-term survival and completely cleared tumors in mouse models, demonstrating its potential in ovarian cancer treatment and laying the groundwork for future clinical trials.
- Stock Surge: Following the positive earnings report and optimistic therapy outlook, Ernexa's shares soared over 90% on Tuesday, reflecting strong market interest in its biotech stock and potentially attracting more investors.
- Clear Future Plans: CEO Sanjeev Luther stated that the company aims to submit an Investigational New Drug application by Q3 2026 and plans to initiate a Phase 1 human trial later this year, indicating ongoing commitment to R&D and strategic direction.
See More
Ernexa's Innovative Advances in Ovarian Cancer Treatment
- Unmet Need in Ovarian Cancer: Dr. Robert Pierce, Chief Scientific Officer of Ernexa, emphasizes the significant unmet need in treating ovarian cancer, one of the most challenging malignancies, highlighting the urgent demand for more effective and durable treatment options to enhance patient quality of life and outcomes.
- Potential of ERNA-101: Recent preclinical data shows that ERNA-101, when combined with PD-1 blockade, achieved a remarkable 100% survival rate and complete tumor elimination in ovarian cancer models, indicating its potential to significantly improve patient prognosis and treatment efficacy.
- Virtual Investor Event: Ernexa will host a Virtual Investor Closing Bell event on May 13, 2026, where executives will present the latest developments of ERNA-101 and discuss its application potential in ovarian cancer treatment, further boosting investor confidence in the company's future growth.
- Innovation in Cell Therapy: Ernexa focuses on developing innovative cell therapies using induced pluripotent stem cell technology to provide scalable treatment solutions, with ERNA-101 designed to activate and regulate the immune response to recognize and attack cancer cells, showcasing its strategic significance in cancer treatment advancements.
See More
Ernexa Therapeutics Exceeds Expectations with Promising Therapy Results
- Therapy Advancement: Ernexa Therapeutics announced that its ERNA-101 cell therapy achieved 100% long-term survival and complete tumor clearance in mouse models, exceeding company expectations and demonstrating significant potential in advanced ovarian cancer treatment.
- Clinical Trial Plans: The company plans to advance ERNA-101 to its first human trial, which is expected to significantly shift treatment outcomes in ovarian cancer and may extend to other immunologically suppressed tumors, enhancing treatment effectiveness.
- Market Reaction: Following the announcement, Ernexa's stock surged 60% on Wednesday, reflecting investor optimism about its preclinical results, with retail sentiment shifting from neutral to extremely bullish, with some expecting a 200% rally.
- Peer Updates: The release of Ernexa's trial results coincided with Zentalis Pharmaceuticals announcing progress in its treatment for platinum-resistant ovarian cancer, further increasing market interest in ovarian cancer therapies.
See More
Ernexa Therapeutics Reports Breakthrough in Cancer Treatment
- Tumor Clearance Rate: Ernexa's ERNA-101 combined with PD-1 blockade achieves a 100% tumor clearance rate in ovarian cancer models, indicating potential curative activity that could transform treatment paradigms for ovarian cancer.
- Microenvironment Remodeling: ERNA-101 remodels the tumor microenvironment from immunosuppressive to immune-activated, enhancing anti-tumor immune responses and suggesting applicability in other solid tumors.
- Enhanced Cell Activity: The therapy significantly boosts the activity and survival of key cancer-fighting T cells, facilitating greater infiltration of CD4⁺ and CD8⁺ T cells into tumors, potentially offering more effective treatment options for patients.
- Clinical Trial Prospects: Ernexa plans to incorporate these positive preclinical findings into its development strategy, advancing ERNA-101 towards a first-in-human clinical trial for advanced ovarian cancer, signaling the company's strategic positioning in tumor immunotherapy.
See More
Ernexa Therapeutics to Implement 1-for-25 Reverse Stock Split
- Reverse Stock Split Plan: Ernexa Therapeutics announced a 1-for-25 reverse stock split effective May 4, 2026, aiming to consolidate every 25 shares into 1 to comply with Nasdaq's minimum bid price requirement of $1, thereby enhancing the stock's market performance.
- Reduction in Shares: This split will reduce the company's outstanding shares from approximately 29.15 million to about 1.17 million, significantly lowering the share count, which may impact investor liquidity and attractiveness towards the stock.
- Market Reaction: Following the reverse split announcement, ERNA shares fell 25% in premarket trading, reflecting market concerns regarding the company's current financial condition and future outlook, which could undermine investor confidence.
- Compliance Pressure: This move not only addresses Nasdaq compliance but also indicates the company's urgency in improving its market image and shareholder value, potentially affecting its future financing and strategic development plans.
See More
